Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Filgrastim | Research article

A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer

Authors: Dongling Zou, Mingfang Guo, Qi Zhou

Published in: BMC Cancer | Issue 1/2021

Abstract

Purpose

To evaluate the effectiveness and safety of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during chemoradiotherapy in patients with cervical cancer.

Methods

From August 2018 to April 2020, 60 patients who were pathologically confirmed as cervical cancer were randomly divided into two groups at a ratio of 2:1: PEG-modified-rhG-CSF experimental group and control group. The primary endpoints were the incidence of grade 3–4 neutropenia. Secondary endpoints included the duration of grade 3–4 neutropenia, the incidence of grade 4 neutropenia, the incidence of febrile neutropenia (FN), delay rate of chemotherapy, prolonged time of chemotherapy, time to complete radiotherapy and safety.

Results

The incidence of grade 3–4 neutropenia in the experimental group was significantly lower than the control group (10% vs. 77.78%, P < 0.001). However, there was no statistical significance between the two groups in the duration of grade 3–4 neutropenia (3.75 days vs. 5.07 days, P = 0.871). The experimental group was better than the control group in the incidence of grade 4 neutropenia, the incidence of FN and delay rate of chemotherapy, and the difference was statistically significant (P < 0.05). Besides, the prolonged time of chemotherapy and the time to complete radiotherapy in the experimental group were less than those in the control group, but the difference was not statistically significant (P > 0.05). The incidence of adverse events in the experimental group and control group were 55.00 and 94.44%, respectively, and the difference was statistically significant (P = 0.003).

Conclusion

PEG-rhG-CSF preventive treatment used in the course of chemoradiotherapy for patients with cervical cancer can reduce the incidence of neutropenia and improve the incidence of delayed chemotherapy cycles.

Trial registration

ClinicalTrials.gov, NCT04542356. Registered 9 September 2020 - Retrospectively registered.

Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86. https://doi.org/10.1093/annonc/mdr015.CrossRefPubMed

Tilahun Y, Lew C, Belayihun B, Lulu Hagos K, Asnake M. Improving contraceptive access, use, and method mix by task sharing Implanon insertion to frontline health workers: the experience of the integrated family health program in Ethiopia. Glob Health Sci Pract. 2017;5(4):592–602. https://doi.org/10.9745/GHSP-D-17-00215.CrossRefPubMedPubMedCentral

Mądry R, Popławska L, Haslbauer F, Šafanda M, Ghizdavescu D, Benkovicova J, et al. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy. Wien Klin Wochenschr. 2016;128(7–8):238–47. https://doi.org/10.1007/s00508-015-0917-1.CrossRefPubMedPubMedCentral

Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802–12.

Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–67. https://doi.org/10.1200/JCO.2006.08.8823.CrossRefPubMed

Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475–84. https://doi.org/10.1093/annonc/mdt226.CrossRefPubMedPubMedCentral

Giebel S, Thomas X, Hallbook H, Geissler K, Boiron JM, Huguet F, et al. The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL. Eur J Cancer. 2012;48(3):360–7. https://doi.org/10.1016/j.ejca.2011.11.023.CrossRefPubMed

Kuwabara T, Kobayashi S, Sugiyama Y. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev. 1996;28(4):625–58. https://doi.org/10.3109/03602539608994020.CrossRefPubMed

CJ XJ, Wang JF, Zhang BH, Zeng XH, Zheng H, Zhang Y, et al. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study. Breast Cancer Res Treat. 2018;168(2):389–99.CrossRef

10.

Takashi Yoshida SN, Ohtake S, Okafuji K, Kobayashi K, Kondo K, Kanno M, et al. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma. Cancer. 1990;66(9):1904–9 10.1002/1097-0142(19901101)66:9<1904::AID-CNCR2820660908>3.0.CO;2-V.CrossRef

11.

Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451–8. https://doi.org/10.1016/S1359-6446(05)03575-0.CrossRefPubMed

12.

Lee KHKJ, Lee MH, Han HS, Lim JH, Park KU, Park IH, et al. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10–09. Support Care Cancer. 2016 Apr;24(4):1709–17. https://doi.org/10.1007/s00520-015-2963-7.CrossRefPubMed

13.

Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin. 2011;27(1):79–86. https://doi.org/10.1185/03007995.2010.536527.CrossRefPubMed

14.

Gabrilove JL. An analysis of current neutropenia therapies, including pegfilgrastim. Clin Cornerstone. 2006;8(Suppl 5):S19–28. https://doi.org/10.1016/S1098-3597(06)80055-4.CrossRefPubMed

15.

Zhai Y, Zhao Y, Lei J, Su Z, Ma G. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight. J Biotechnol. 2009;142(3–4):259–66. https://doi.org/10.1016/j.jbiotec.2009.05.012.CrossRefPubMed

16.

Zhou CHY, Wang D, An C, Zhou F, Li Y, Chen G, et al. A randomized multicenter phase III study of single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim biosimilar, for prophylaxis of chemotherapy-induced neutropenia in patients with advanced non-small-cell lung Cancer (NSCLC). Clin Lung Cancer. 2016;17(2):119–27. https://doi.org/10.1016/j.cllc.2015.12.002.CrossRefPubMed

17.

Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35. https://doi.org/10.1093/annonc/mdg019.CrossRefPubMed

18.

Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003;21(3):514–9. https://doi.org/10.1200/JCO.2003.03.040.CrossRefPubMed

19.

Huang W, Liu J, Zeng Y, Wu F, Li N, Chen K, et al. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer. Cancer Chemother Pharmacol. 2018;82(4):607–13. https://doi.org/10.1007/s00280-018-3639-z.CrossRefPubMed

20.

Sekine ISM, Ito Y, Horinouchi H, Nokihara H, Yamamoto N, Kunitoh H, et al. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):953–9. https://doi.org/10.1016/j.ijrobp.2011.01.008.CrossRefPubMed

21.

Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, et al. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer. 2015;23(7):2045–51. https://doi.org/10.1007/s00520-014-2555-y.CrossRefPubMed

22.

Liu F, Du Y, Cai B, Yan M, Yang W, Wang Q. A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy. J Cancer Res Ther. 2017;13(5):790–5. https://doi.org/10.4103/jcrt.JCRT_320_17.CrossRefPubMed

23.

Beesley VL, Smith DD, Nagle CM, Friedlander M, Grant P, DeFazio A, et al. Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. Support Care Cancer. 2018;26(12):4133–42. https://doi.org/10.1007/s00520-018-4284-0.CrossRefPubMed

24.

Chunyun Z, Jie S, Wu Y, Shen W, Yongming C, Duanyuan S, et al. Pharmacokinetics and pharmacodynamics study of PEGylated recombinant human granulocyte colony-stimulating factor injection in healthy volunteers. Drugs Clin. 2017;32(9):1614–9.

Title: A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer
Authors: Dongling Zou
Mingfang Guo
Qi Zhou
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Filgrastim
Cervical Cancer
Neutropenia
Cervical Cancer
Radiotherapy
Filgrastim
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08364-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

LINC_00355 promotes gastric cancer progression by upregulating PHF19 expression through sponging miR-15a-5p

Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens

Cancer-associated mutations reveal a novel role for EpCAM as an inhibitor of cathepsin-L and tumor cell invasion

Super-enhancer-associated long noncoding RNA AC005592.2 promotes tumor progression by regulating OLFM4 in colorectal cancer

SMAD4 haploinsufficiency in small intestinal neuroendocrine tumors

Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer